Ownership history in Commodore Capital LP · 12 quarters on record
This page tracks every 13F SEC filing in which Commodore Capital LP reported a position in ENLIVEN THERAPEUTICS INC (ELVN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | UNCHANGED | 4,692,809 | — | 0% | 4.81% | $72.3M | $15.40 |
| 2025 Q3 | UNCHANGED | 4,692,809 | — | 0% | 4.69% | $96.1M | $20.47 |
| 2025 Q2 | ADDED | 4,692,809 | +17,809 | +0.4% | 6.64% | $94.1M | $20.06 |
| 2025 Q1 | ADDED | 4,675,000 | +470,000 | +11.2% | 6.78% | $92.0M | $19.68 |
| 2024 Q4 | ADDED | 4,205,000 | +105,000 | +2.6% | 6.93% | $94.6M | $22.50 |
| 2024 Q3 | ADDED | 4,100,000 | +126,755 | +3.2% | 6.54% | $104.7M | $25.54 |
| 2024 Q2 | UNCHANGED | 3,973,245 | — | 0% | 6.34% | $92.9M | $23.37 |
| 2024 Q1 | ADDED | 3,973,245 | +1,071,429 | +36.9% | 4.67% | $69.9M | $17.59 |
| 2023 Q4 | UNCHANGED | 2,901,816 | — | 0% | 3.47% | $40.2M | $13.84 |
| 2023 Q3 | ADDED | 2,901,816 | +553,544 | +23.6% | 4.63% | $39.6M | $13.66 |
As of 2025 Q4 — sorted by position size